vision loss with glp 1 Researchers Find Small Increased Risk of Sudden Associated GLP-1 Medications Popular weight-loss drugs linked to

PALO ALTO, Calif., September 28, 2023 (BUSINESS WIRE)-- Digbi Health, the leader in precision biology-based telehealth care for three of the top four healthcare costs - Obesity, T2D, and Digestive Health - announced today the launch of its latest innovation in obesity care, Digbi GLP-Fit, a scientifically-backed approach to identify the best treatment path for an individual to prevent and treat obesity. Key Highlights: Digbi GLP-Fit uses the science of precision biology to identify the best treatment path for obesity for an individual with 87% accuracy, which may include 1) only precision nutrition, 2) a combination of precision nutrition and lower-cost drugs like Metformin, or 3) a combination of precision nutrition and GLP-1 medications

Een nieuwe studie, die onlangs is gepubliceerd in JAMA Network Open, suggereert dat GLP-1 (glucagon-like peptide-1) receptoragonisten, die momenteel goedgekeurd zijn voor de behandeling van diabetes en obesitas, mogelijk een bijkomend voordeel hebben: ze kunnen het risico op bepaalde met obesitas geassocieerde kankers (obesity associated cancers, OACs) verminderen

The Pentelute Lab aims to invent new chemistry for the efficient and selective modification of proteins, to hijack these biological machines for efficient drug delivery into cells and to create new machines to rapidly and efficiently manufacture peptides and proteins.

Ozempic (semaglutide) is an FDA-approved glucagon-like peptide-1 receptor agonist (GLP-1) receptor agonist made by Novo Nordisk